Fingolimod for the treatment of relapsing multiple sclerosis

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

(2010) Trina A. Johnson et al.   CLINICAL IMMUNOLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

Burden of illness of diabetic macular edema: literature review

(2010) Er Chen et al.   CURRENT MEDICAL RESEARCH AND OPINION

Glatiramer Acetate

(2010) Natalie J. Carter et al.   DRUGS

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

What is the risk of permanent disability from a multiple sclerosis relapse?

(2010) K. Bejaoui et al.   NEUROLOGY

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis

(2010) M. Mehling et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factors that influence adherence with disease-modifying therapy in MS

(2009) Katherine Treadaway et al.   JOURNAL OF NEUROLOGY

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

(2009) G Giovannoni et al.   Multiple Sclerosis Journal

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

(2009) G. Comi et al.   Multiple Sclerosis Journal

Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study

(2009) A. R. Pachner et al.   NEUROLOGY

Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

(2009) P. O'Connor et al.   NEUROLOGY

Sphingolipids in the Lungs

(2008) Stefan Uhlig et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Multiple Sclerosis: An Immune or Neurodegenerative Disorder?

(2008) Bruce D. Trapp et al.   Annual Review of Neuroscience

Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2008) D. S. Goodin et al.   NEUROLOGY

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY

Interleukin-17 Production in Central Nervous System-Infiltrating T Cells and Glial Cells Is Associated with Active Disease in Multiple Sclerosis

(2007) John S. Tzartos et al.   AMERICAN JOURNAL OF PATHOLOGY

FTY720 modulates human oligodendrocyte progenitor process extension and survival

(2007) Veronique E. Miron et al.   ANNALS OF NEUROLOGY